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South Africa (SA)’s apartheid era saw disparities in the public and 
private health sectors.[1] By 1990, the private sector was responsible 
for 80% of SA’s total medicine expenditure.[2] In 1994, the new 
democratically elected government, faced with problems, e.g. lack 
of equity in access to essential medicines and rising medicine 
prices, decided to tackle these problems systematically through the 
development and implementation of the national drug policy.[2]
In December 1997, the SA government promulgated legislation 
aimed at lowering the cost of medicines to all South Africans.[3] This 
legislation made provision for the establishment of the Medicine 
Pricing Committee (MPC), which makes recommendations on the 
introduction of a transparent pricing system for all medicines sold in 
SA.[3] In 2004, ‘Regulations relating to a transparent pricing system 
for medicines and scheduled substances’ were promulgated.[4] These 
new regulations introduced single exit pricing (SEP) as a mechanism 
to improve medicine price transparency. The overall aim of SEP was 
to improve access to medicines by reducing prices of innovator and 
generic medicines and to control price increases.[4] 
Although medicine pricing policies may aim to keep medicines 
accessible, regulating medicine prices may have various effects on 
the availability of medicine.[5,6] It may increase or decrease or have 
a negligible effect on the availability of medicines to the patient. 
Pricing regulations have led to a lower level of new medicine 
introductions and to market withdrawal of some products, which 
may increase the vulnerability of the pharmaceutical market to 
medicine shortages.[5,6] The impact of medicine price controls 
has been extensively described in high-income markets with well-
developed universal health coverage systems and those that exercise 
price control on predominately reimbursed medicines.[7-9] Pricing 
policies in the European Union (EU) have successfully reduced the 
cost of medicines for health funders and patients. These policies 
have also led to unforeseen factors, such as parallel export of 
medicines from lower-priced markets, a stricter supply chain with 
regard to keeping smaller inventories and reducing costs, and some 
manufacturers removing medicines or not introducing them to 
lower-priced markets.[5,6]
There is limited literature addressing the impact of medicine price 
controls in low- and middle-income countries, where a significant 
portion of patients are without healthcare insurance and incur 
considerable out-of-pocket expenditure for medicines.[10] In the SA 
private sector context, this is further compounded by the uniqueness 
of the price controls adopted, where all medicine prices (whether 
reimbursed or not) are controlled (with the exception of schedule 0 
medicines, which are exempt). The introduction of SEP in SA realised 
an average reduction of 22% in the price of medicines; however, a 
consistent pricing benefit was not realised by consumers.[11] Research 
on community pharmacies by Pretorius[11] further established that, 
with a reduction in overall gross profit generated by pharmacies, the 
pressure on the business environment was evident. 
A survey conducted by Naudé and Luiz in 2013[12] found that 
price controls in SA reduced profit margins on medicines that are 
sold locally, which resulted in pressure on suppliers to increase their 
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economies of scale to reduce the cost per unit produced. Importantly, 
they also observed that some companies discontinued the production 
of certain products, as it no longer remained economically viable 
to produce these locally. Our research presents the impact of 
medicine price controls in the form of SEP on medicine product 
discontinuation on the SA private healthcare market. For this 
study, medicine discontinuation also refers to medicine withdrawal. 
Therefore, the objective of the study was to evaluate the impact of SEP 
legislation on the availability of medicines on the private health sector 
market in SA in terms of withdrawal of medicines from the market.
Methods
A quantitative analysis of all registered medicines on the SA private 
sector market by stock-keeping units (SKUs) was done to identify 
medicine products withdrawn from the market by SKUs. An SKU is 
a service identification code for a store or product, often portrayed 
as a machine-readable barcode that helps to track the item for an 
inventory. An SKU does not need to be assigned to physical products 
in an inventory. Different pack sizes of a product are defined by 
separate SKU codes.
A comprehensive list of all marketed medicines on the SA private 
sector market by SKUs was obtained from a medical database 
managed by medical data specialists (Medprax, SA), who supply 
essential up-to-date medicine price data for the SA healthcare 
industry. The dataset consisted of all medicines by SKU, sche dule 1 - 8, 
from 2001 to 2014, which were marketed, withdrawn or flagged 
for withdrawal (in the system) at a time point within the period 
described. Schedule 0 products were excluded, as these are exempt 
from price controls.
Data were entered into Microsoft Excel, version 2016 (Microsoft 
Inc., USA) in a format developed for this study. Discontinued SKUs 
were identified, and the subset was then analysed. The data were 
analysed and summarised descriptively using frequency tables and 
graphs. Discontinued SKUs were grouped by innovator and generic 
companies and then by anatomical therapeutic chemical (ATC) 
classification, and summarised descriptively using frequency tables 
and graphs. All statistical procedures were performed in Microsoft 
Excel. 
Ethical approval
The study was granted ethical clearance by the Human and Social 
Sciences Research Ethics Committee, University of KwaZulu-Natal, 
Durban, SA (ref. no. HSS/0154/013).
Results
A total of 152 manufacturers discontinued at least one SKU between 
2001 and 2014. The majority of identified manufacturers produced 
only generic medicine (n=96; 63.16%) and are classified as generic 
manufacturers. Manufacturers producing patent medicines accounted 
for 36.84% (n=56) and were classified as innovator manufacturers 
(Table 1). A total of 3 691 SKUs was discontinued during the study 
period. Innovator manufacturers accounted for 41.89% (n=1 546) of 
all SKUs discontinued, with generic manufacturers being responsible 
for 2 145 (58.11%) discontinuations (Table1).
The analysis showed that the number of discontinued SKUs ranged 
from 123 to 603. The mean number of discontinuations for generic 
manufacturers was 22.34 (standard deviation (SD) 58.11), while 
innovator manufacturers discontinued a mean of 27.61 (41.89). The 
t-test showed that there was no statistically significant difference 
between the means (t ‒0061; p=0.27) (Table 2). The largest number 
of SKUs was commercially withdrawn in 2002 (n=603), followed 
by discontinuations in 2003 (n=463) and in 2004 (n=407). Generic 
manufacturers consistently discontinued more SKUs each year, 
except in 2003 and 2005 (Table 2).
The majority (70.71%) of discontinued SKUs fell into five 
ATC classes, i.e. anti-infectives for systemic use; nervous system; 
respiratory system; cardiovascular system; and alimentary tract and 
metabolism medicines. A total of 2 610 discontinued SKUs fell into 
these classes, with 2002 (n=406), 2003 (n=324) and 2004 (n=309) 
experiencing the highest number of SKU discontinuations (Table 3). 







discontinued, n Total, N
2001 73 94 167
2002 289 314 603
2003 248 215 463
2004 154 253 407
2005 132 97 229
2006 103 164 267
2007 70 213 283
2008 94 192 286
2009 56 92 148
2010 95 113 208
2011 65 89 154
2012 58 93 151
2013 49 74 123
2014 60 122 182
SKUs = stock-keeping units.
Table 3. Discontinued SKUs classified by the ATC system
ATC classification n (%)
Anti-infectives for systemic use 848 (22.97)
Nervous system 578 (15.66)
Respiratory system 490 (13.28)
Cardiovascular system 368 (9.97)
Alimentary tract and metabolism 326 (8.83)
Musculoskeletal system 261 (7.07)
Antineoplastic and immunomodulating agents 156 (4.23)
Dermatologicals 138 (3.74)
Genito-urinary system and sex hormones 123 (3.33)
Various 107 (2.90)
Sensory organs 89 (2.41)
Systemic hormonal preparations, excluding  
sex hormones and insulins
75 (2.03)
Blood and blood-forming organs 67 (1.82)
Antiparasitic products, insecticides and repellents 65 (1.76)
Total 3 691 (100)
SKUs = stock-keeping units; ATC = anatomical therapeutic chemical.
Table 1. SKUs discontinued by designated manufacturer
Manufacturer Product, n SKUs discontinued, n Mean (SD)
Generic 96 2 145 22.34 (58.11)
Innovator 56 1 546 27.61 (41.89)
Combined 152 3 691 24.28 (55.55)
SKUs = stock-keeping units; SD = standard deviation.
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Medicine SKUs in the anti-infectives for 
systemic use class, accounted for the largest 
number of discontinued SKUs (n=848). 
Generic manufacturers discontinued 
a consistently higher number of SKUs in 
this class from 2001 to 2014. The highest 
number of generic anti-infective SKUs were 
discontinued in 2002 (n=68), 2004 (n=79) 
and 2007 (n=47). The highest number of 
innovator anti-infective SKUs discontinued 
occurred in 2002 (n=23) and 2003 (n=31). 
The highest number of discontinuations 
for cardiovascular medicines was evident 
in 2002 (n=48), 2007 (n=39) and 2010 
(n=37). Medicines acting on the renin-
angiotensin system was the largest class 
of such medicines that were discontinued 
(n=94). This was followed by beta-blockers 
(n=61), while the third-highest discontinued 
class was diuretics (n=48).
The relationship between number 
of discontinued SKUs per year and 
increase in SEP was investigated, with the 
number of SKUs discontinued being the 
dependent variable (y). The regression line 
was determined to be as follows: SKUs 
discontinued: ‒14.06 (SEP increase) + 
309.89 (Fig. 1). The regression line showed 
a negative relationship, with a Pearson’s 
correlation coefficient r ‒0.414 (p=0.14). 
Our analysis showed that 10 SKUs (7 onco -
logy molecules) that were withdrawn are 
no longer on the market, i.e. there was 
an identical molecule available after the 
product was discontinued (from the same or 
different manufacturer).
Discussion
The results from the analysis showed that 
generic and innovator manufacturers 
commercially withdrew SKUs during the 
study period, but prior to the implementation 
of the SEP legislation in 2004. Three 
generic manufacturers were responsible for 
withdrawing most of the SKUs. Generic 
manufacturers have a high vulnerability to 
price; therefore, a possible reason for the 
high number of generic SKU withdrawals 
could be price reductions, where it is no 
longer financially sustainable to produce 
the SKU.[13] 
The highest number of SKUs were 
withdrawn in the years shortly before the 
implementation of SEP (2002 - 2004) ‒ 
consistent for generics and innovator 
medicines. In 2001, an industry body, the 
Pharmaceutical Manufacturers Association, 
withdrew its longstanding legal battle 
against the implementation of amendments 
to legislation that would enable pricing 
transparency, including SEP, which was 
finally legislated in April 2004.[4] The high 
number of SKU withdrawals between 
2002 and 2004 could have been due to a 
reaction by pharmaceutical manufacturers 
anticipating the imminent medicine price 
regulation by SEP legislation.
A strategy employed by pharmaceutical 
manufacturers to maximise profits (and a 
reason for commercial withdrawal), is SKU 
rationalisation. SKU rationalisation can be 
viewed as an effort by a company to maintain 
fewer SKUs of the same product, such that 
they only market the most profitable SKUs. 
This is especially true of the SA market, 
as SEP is applied to a single unit dose and 
not to pack-size; therefore, reduction in 
cost to the manufacturer is seen in terms 
of packaging components, material and 
packaging operations. 
Anti-infective, cardiovascular and 
antiretroviral (ARV) medicines are three 
therapeutic classes associated with high 
usage and expenditure in the SA private 
health sector.[14] Our analysis revealed that 
anti-infective and cardiovascular drugs 
accounted for 22.97% and 9.97% of all SKU 
withdrawals, respectively. The majority of 
the withdrawn SKUs in the cardiovascular 
class was antihypertensives. This should be 
seen as hypertension having a very high 
prevalence (129.9/1 000) in SA.[14] Anti-
infective medicines follow a similar trend, 
with most withdrawn SKUs being the most-
used antibiotics, i.e. beta-lactam antibiotics.[14]
Safety is another, albeit less common, 
reason for the voluntary withdrawal of a 
medicine from the market. In SA, between 
2001 and 2014, very few medicines were 
completely withdrawn from the market owing 
to safety reasons. Two anti-inflammatory 
medicines, valdecoxib and rofecoxib, were 
withdrawn in 2004 owing to evidence that 
they increased the risk of heart attack and 
stroke. In 2011, an anti-diabetic medicine, 
rosiglitazone, and dextropropoxyphene-
containing products were withdrawn, 
because of cardiac concerns. The small 
number of safety withdrawals during the 
study period is consistent with findings of 
studies that analysed medicine withdrawal 
due to safety reasons.[15]
It may be plausible also to consider that 
changes to clinical guidelines, e.g. ARV and 
fixed-dose-combination guidelines, may 
have had an impact on the discontinuation 
of certain products. Furthermore, one 
should consider that some products may 
have been highly genericised, with many 
competitors for one molecule. This type of 
crowded market and downward pressure on 
price may be another reason why some SKUs 
were withdrawn, and that withdrawal was 
not primarily based on SEP policy.
SEP is further regulated by a fixed, 
allowable, maximum annual increase, 
which is published after consultation with 
the MPC, and with consideration of the 
average consumer price index (CPI ) for 
the preceding year, the average producer 
price index (PPI) for the preceding year, 
changes in the rates of foreign exchange and 
purchasing power parity, and international 
pricing information.[4] A chief executive 
officer of a leading SA generic company 
remarked to the Business Day in January 
2018, in response to the annual SEP increase 
of 1.26%, that ‘continued pressure on the 
industry also leads to products being pulled 
from the market, which means a smaller 
variety of quality, affordable medicines for 
patients’.[16] 
Our analysis showed that a total of 3 691 
SKUs was discontinued during 2001 - 2014, 
with the highest number of withdrawals 
between 2002 and 2004 – shortly before the 
implementation of SEP. During the following 
years, there was a 4.19% yearly average price 





















Fig. 1. Scatter plot and line between the dependent variable number of SKUs discontinued and the 
independent variable percentage SEP increase. (SKU = stock-keeping units; SEP = single exit pricing.)
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increase, with the MPC publishing a 0% increase in 2004, 2005, 2006 
and 2011. An increase of 5.2% was published in 2007, almost 3 years 
after implementation of the pricing regulation. Bearing in mind the 
annual increases that were gazetted each year, it is interesting to note 
that from our analysis, generic medicines showed the highest number 
of product withdrawals during 2002 - 2008, with 1 448 of a total 
of 2 145 for that period. Innovator medicine withdrawals during the 
same period were also high, with 1 090 of a total of 1 546. The highest 
SEP annual increase occurred in 2009 (13.2%). In 2009, the innovator 
withdrawals from the market was the lowest since 2002.
In addition to SEP increases, the reduction of SKU withdrawals 
between 2009 and 2014 may have been driven by the strengthening 
of the ZAR against the USD. The ZAR showed great strength in 
recovery in 2009, trading at ZAR8.07 to the USD after lows hovering 
around ZAR10.00 to the USD at the end of 2008. The lower number 
of SKUs discontinued, could have been due to the stable exchange 
rate and SEP price increases that were gazetted during this time.
Our analysis included testing whether the yearly increase in SEP 
may have had a direct effect of the number of SKUs withdrawn 
during the study period. The linear regression used to assess if there 
was a correlation between the yearly SEP increase and the number 
of SKUs withdrawn, revealed a negative correlation, i.e. as the yearly 
percentage SEP increase improved, the number of SKU withdrawals 
decreased. This was further confirmed by Pearson’s correlation 
coefficient (r ‒0.414); however, the correlation was not statistically 
significant (p=0.14).
Medicine pricing policies may have a dual impact on the market. 
Policies are typically aimed at making medicines more affordable for 
the patient; however, pricing policies may have a negative effect on 
medicine availability. The results show that SEP and a transparent 
pricing policy may have had an impact on SKU withdrawal from the 
market as a policy option prior to implementation. 
In summary, our analysis shows that, although the anticipated 
introduction of SEP might have been the cause of product 
withdrawals, the limited annual price increases have not resulted in 
significantly increased withdrawals from the market, as predicted 
by manufacturers. Therefore, from this analysis it appears that the 
ongoing SEP regulations have not had a significant impact on access 
to medicines.
Study limitations
A limitation of the study was that the dataset did not allow for 
analysis of the availability or lack thereof of a discontinued molecule/
generic equivalent on the market after the discontinuation of one 
brand. This study analysed SKU withdrawals from the market and 
not entire products, i.e. a product may have remained on the market 
with fewer SKUs or one SKU. The impact on the patient in terms of 
cost, quality and medicine options has to be further analysed. The 
study could not determine if an SKU was withdrawn early on in the 
implementation phase and reintroduced later. Moreover, the study 
did not consider delayed entry into the market as a result of pricing 
policy interventions.
Conclusions 
According to the World Health Organization/Health Action 
International project on medicine prices and availability,[17] low prices 
can reduce the attractiveness of certain countries to manufacturers 
and importers, which may result in important products not being 
produced and marketed in a particular country or being marketed 
with substantial delays. The result of reduced product availability 
and its impact on the cost and quality of healthcare to the patient, 
need to be regularly monitored and evaluated to ascertain if direct 
price regulations achieve the intended outcomes. Other intended or 
unintended effects in pharmaceutical market dynamics should also 
be evaluated. Analysis of the number, timing and trend regarding new 
product launches would augment the body of evidence related to the 
market effects of SEP. This analysis would be valuable in exploring 
the impact of a legislated medicine pricing model on withdrawal 
and the effects of the availability of new medicines to the SA patient. 
Finally, while the anticipation of SEP in 2002 - 2004 led to higher 
product withdrawals before it was implemented, one cannot state that 
ongoing SEP implementation and the regulated annual increases have 
caused significant withdrawals of products from the market.
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